Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
30
09
2021
accepted:
08
08
2022
pubmed:
11
9
2022
medline:
15
12
2022
entrez:
10
9
2022
Statut:
ppublish
Résumé
This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC). Medical records and follow-up data from 190 patients were gathered retrospectively. All patients had surgery at pOC and at least one further rOC surgery at four European high-volume centers. Patients were divided into one cohort with confirmed mutation for BRCA1 and/or BRCA2 (BRCAmut) and a second cohort with BRCA wild type or unknown (BRCAwt). Patterns of tumor presentation, surgical outcome and survival data were analyzed between the two groups. Patients with BRCAmut disease were on average 4 years younger and had significantly more tumor involvement upon diagnosis. Patients with BRCAmut disease showed higher debulking rates at all stages. Multivariate analysis showed that only patient age had significant predictive value for complete tumor resection in pOC. At rOC, however, only BRCAmut status significantly correlated with optimal debulking. Patients with BRCAmut disease showed significantly prolonged overall survival (OS) by 24.3 months. Progression-free survival (PFS) was prolonged in the BRCAmut group at all stages as well, reaching statistical significance during recurrence. Patients with BRCAmut disease showed a more aggressive course of disease with earlier onset and more extensive tumor dissemination at pOC. However, surgical outcome and OS were significantly better in patients with BRCAmut disease compared with patients with BRCAwt disease. We therefore propose to consider BRCAmut status in regard to patient selection for cytoreductive surgery, especially in rOC.
Sections du résumé
BACKGROUND
BACKGROUND
This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC).
PATIENTS AND METHODS
METHODS
Medical records and follow-up data from 190 patients were gathered retrospectively. All patients had surgery at pOC and at least one further rOC surgery at four European high-volume centers. Patients were divided into one cohort with confirmed mutation for BRCA1 and/or BRCA2 (BRCAmut) and a second cohort with BRCA wild type or unknown (BRCAwt). Patterns of tumor presentation, surgical outcome and survival data were analyzed between the two groups.
RESULTS
RESULTS
Patients with BRCAmut disease were on average 4 years younger and had significantly more tumor involvement upon diagnosis. Patients with BRCAmut disease showed higher debulking rates at all stages. Multivariate analysis showed that only patient age had significant predictive value for complete tumor resection in pOC. At rOC, however, only BRCAmut status significantly correlated with optimal debulking. Patients with BRCAmut disease showed significantly prolonged overall survival (OS) by 24.3 months. Progression-free survival (PFS) was prolonged in the BRCAmut group at all stages as well, reaching statistical significance during recurrence.
CONCLUSIONS
CONCLUSIONS
Patients with BRCAmut disease showed a more aggressive course of disease with earlier onset and more extensive tumor dissemination at pOC. However, surgical outcome and OS were significantly better in patients with BRCAmut disease compared with patients with BRCAwt disease. We therefore propose to consider BRCAmut status in regard to patient selection for cytoreductive surgery, especially in rOC.
Identifiants
pubmed: 36085390
doi: 10.1245/s10434-022-12459-3
pii: 10.1245/s10434-022-12459-3
pmc: PMC9726811
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
35-45Subventions
Organisme : European Commission
ID : 279113
Informations de copyright
© 2022. The Author(s).
Références
Sehouli J, Grabowski JP. Surgery for recurrent ovarian cancer: options and limits. Best Pract Res Clin Obstet Gynaecol. 2017;41:88–95.
doi: 10.1016/j.bpobgyn.2016.10.009
Capozzi VA, Rosati A, Turco LC, Sozzi G, Riccò M, Chiofalo B, et al. Surgery vs chemotherapy for ovarian cancer recurrence: what is the best treatment option. Gland Surg. 2020;9(4):1112–7.
doi: 10.21037/gs-20-326
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgaard BJ, Selle F, Guyon F, Pomel C, Lécuru F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, du Bois A; DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2 Dec 2021;385(23):2123–2131. https://doi.org/10.1056/NEJMoa2103294 . Erratum in: N Engl J Med. 17 Feb 2022;386(7):704.
Muallem MZ, Gasimli K, Richter R, Almuheimid J, Nasser S, Braicu EI, et al. AGO score as a predictor of surgical outcome at secondary cytoreduction in patients with ovarian cancer. Anticancer Res. 2015;35(6):3423–9.
Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10.
doi: 10.1245/s10434-006-9058-0
Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289–95.
doi: 10.1097/IGC.0b013e31820aaafd
Janco JM, Kumar A, Weaver AL, McGree ME, Cliby WA. Performance of AGO score for secondary cytoreduction in a high-volume U.S. center. Gynecol Oncol. 2016;141(1):140–7.
doi: 10.1016/j.ygyno.2016.01.027
Harter P, Beutel B, Alesina PF, Lorenz D, Boergers A, Heitz F, et al. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol Oncol. 2014;132(3):537–41.
doi: 10.1016/j.ygyno.2014.01.027
Bogani G, Tagliabue E, Signorelli M, Ditto A, Martinelli F, Chiappa V, et al. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses. J Gynecol Oncol. 2018;29(3):e40.
doi: 10.3802/jgo.2018.29.e40
Sehouli J, Richter R, Braicu EI, Buhling KJ, Bahra M, Neuhaus P, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol. 2010;102(6):656–62.
doi: 10.1002/jso.21652
Knabben L, Imboden S, Mueller MD. Genetic testing in ovarian cancer—clinical impact and current practices. Horm Mol Biol Clin Investig. 2019;41(3).
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31(9):1148–59.
doi: 10.1016/j.annonc.2020.06.004
Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. New Eng J Med. 2018;379(26):2495–505.
doi: 10.1056/NEJMoa1810858
Bickell NA, Egorova N, Prasad-Hayes M, Franco R, Howell EA, Wisnivesky J, et al. Secondary surgery versus chemotherapy for recurrent ovarian cancer. Am J Clin Oncol. 2018;41(5):458–64.
doi: 10.1097/COC.0000000000000310
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New Eng J Med. 2019;381(25):2416–28.
doi: 10.1056/NEJMoa1911361
Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res. 2019;12(1):9.
doi: 10.1186/s13048-019-0484-6
Marchetti C, Minucci A, Pietragalla A, Scambia G, Fagotti A. BRCA status assessment in epithelial ovarian cancer and the challenge of tumor testing. Int J Gynecol Cancer. 2020;30(9):1465–6.
doi: 10.1136/ijgc-2020-001670
Giudice MT, D’Indinosante M, Cappuccio S, Gallotta V, Fagotti A, Scambia G, et al. Secondary cytoreduction in ovarian cancer: who really benefits? Arch Gynecol Obstet. 2018;298(5):873–9.
doi: 10.1007/s00404-018-4915-1
Kurman RJ, International Agency for Research on Cancer., World Health Organization. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC Sci Publ; 2014. 307 p.p.
Sehouli J, Konsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, et al. “IMO”–intraoperative mapping of ovarian cancer. Zentralbl Gynakol. 2003;125(3–4):129–35.
Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. J Gynecol Oncol. 2007;107(1):99–106.
doi: 10.1016/j.ygyno.2007.05.032
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
doi: 10.1016/j.ejca.2008.10.026
Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol Oncol. 2017;146(1):58–63.
doi: 10.1016/j.ygyno.2017.04.011
Jorge S, Swisher EM, Norquist BM, Pennington KP, Gray HJ, Urban RR, et al. Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations. Gynecol Oncol Rep. 2019;29:113–7.
doi: 10.1016/j.gore.2019.08.001
Marchetti C, De Leo R, Musella A, D’Indinosante M, Capoluongo E, Minucci A, et al. BRCA mutation status to personalize management of recurrent ovarian cancer: a multicenter study. Ann Surg Oncol. 2018;25(12):3701–8.
doi: 10.1245/s10434-018-6700-6
Ataseven B, Tripon D, Schwameis R, et al. Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA 1/2-mutation—real life data. Gynecol Oncol. 2021;163(3):569–77.
doi: 10.1016/j.ygyno.2021.09.004
Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002;20(2):463–6.
doi: 10.1200/JCO.2002.20.2.463
Kubelac P, Vlad C, Berindan Neagoe I, Irimie A, Achimas Cadariu P. The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients. JBUON. 2019;24(4):1538–43.
Xu K, Yang S, Zhao Y. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Oncotarget. 2017;8(1):285–302.
doi: 10.18632/oncotarget.12306
Ashour M, Ezzat Shafik H. Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome. Cancer Manag Res. 2019;11:6275–84.
doi: 10.2147/CMAR.S206817
Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, et al. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol. 2012;126(2):224–8.
doi: 10.1016/j.ygyno.2012.05.001
Estati FL, Pirolli R, de Alencar VTL, Ribeiro ARG, Formiga MN, Torrezan GT, et al. Impact of BRCA1/2 mutations on the efficacy of secondary cytoreductive surgery. Ann Surg Oncol. 2020;28:3637–45.
doi: 10.1245/s10434-020-09366-w
Shi T, Zhu J, Feng Y, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):439–49.
doi: 10.1016/S1470-2045(21)00006-1
Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–91.
doi: 10.1016/S1470-2045(17)30279-6
Marchetti C, Rosati A, Scaletta G, Pietragalla A, Arcieri M, Ergasti R, et al. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study. Gynecol Oncol. 2019;155(3):400–5.
doi: 10.1016/j.ygyno.2019.09.020